NCT01263418View on ClinicalTrials.gov

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2018

Conditions
Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, B-Cell, Marginal ZoneLymphoma, Low-GradeLymphoma, Intermediate-Grade
Interventions
DRUG

Ofatumumab

Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT01263418 - Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | Biotech Hunter | Biotech Hunter